Abstract: A use of plant exosomes as a product having the effect of enhancing viability and, by stimulating the hair follicles, enhancing hair growth in skin cells. The plant exosomes are used to revitalize and strengthen unhealthy skin and hair that have lost their vitality, to stop hair loss, to provide faster hair growth by stimulating hair follicles, and to provide a regulating effect in improving the effects such as wrinkles and age spots caused by aging skin cells. The plant exosomes are isolated from single, double, or triple combinations of plants selected from a group consisting of pineapple plant, garlic plant, and pomegranate plant. For example, a triple combination includes 1 ng-1 mg of the plant exosomes isolated from the pineapple plant, 1 ng-10 ?g of the plant exosomes isolated from the garlic plant, and 1 ng-1 mg of plant exosomes isolated from the pomegranate plant.

Abstract: An adjuvant composition for a vaccine includes one or more substantially isoparaffinic hydrocarbon oils having C17 and/or C18 isoparaffins, and one or more surfactants. A vaccine includes the adjuvant composition.

Abstract: The present application relates to an adjuvant which is suitable to be used in vaccines or other immunogenic compositions. Specifically, the adjuvant promotes the induction of interleukin-1 (IL-1), type 1 interferons (IFNs), such as IFN?, and IFN?, type 2 interferons, such as IFN? and/or tumour necrosis factor (TNF) response, such as TNF?, and elicits or enhances an immune response, preferably in neonatal, juvenile or paediatric animal and/or human populations.

Abstract: This disclosure provides compositions and methods for stimulating the innate immune response in a subject with agents capable of stimulating an innate immune response in a subject upon administration to the subject (e.g., damage-associated molecular patterns (DAMPs) and pathogen-associated molecular patterns (PAMPs)). In particular, the present invention is directed to compositions of DAMPs/PAMPs and metals ions, as well as systems and methods utilizing such nanoparticles (e.g., in diagnostic and/or therapeutic settings).

Abstract: Provided herein are dry powder formulations comprising at least one active pharmaceutical ingredient suitable for nasal application. Also provided are unit dose forms and devices comprising such formulations and methods of using such formulations for the treatment of various conditions including respiratory conditions, hemodynamic collapse, seizures, migraines, and other conditions.

Abstract: Provided herein, in some embodiments, are nucleic acid nanostructure-based vaccines.

Abstract: Compositions and methods for treating hair loss and/or nail brittleness, fragility, and pitting, particularly in pediatric patients, using topically administered JAK/STAT inhibitors and one or more penetration enhancer are described herein.

Abstract: The use of long-chain alkenones to impart desired characteristics in personal care compositions for topical applications is described. The preparation of mixtures long-chain alkenones and synthetic derivatives thereof is presented. Examples of compositions include abrasive soaps, with alkenones serving as natural exfoliating agents. Alkenones and their derivatives can serve as emollients, occlusive agents, stabilizing agents, binding agents, thickening agents, surfactants, and antimicrobials.

Abstract: Provided are an immunomodulatory CpG ODN chemically modified by means of a structure as shown by general formula I and the use thereof. The CpG ODN has an immunostimulatory activity, can stimulate the proliferation of B cells, and produce specific cytokines. The above-mentioned CpG ODN can be used as a vaccine adjuvant alone or in combination with other adjuvants to exert a synergistic effect, and can also be used in the preparation of drugs for preventing or treating tumors, infections, and allergies.

Abstract: The present discovery pertains generally to the field of therapeutic compounds. More specifically the present discovery pertains to certain di-isopropyl-phosphinoyl-alkanes as described herein, DIPA-1-7, DIPA-1-8, and DIPA-1-9, collectively referred to herein as “DIPA compounds”, that are useful, for example, in the treatment of the discomforts of dermatological disorders (e.g., diseases) The treatment is for the dysesthesia (e.g., caused by irritation, itch, or pain) due to dermatitis, urticaria; scalp itch; vulvar itch; lichen sclerosus; cholestatic itch; psoriasis; sebhorrheic dermatitis; allergic conjunctivitis; blepharitis; and pruritus of the elderly. The applicant has found that topical delivery of DIPA compounds to the skin alleviates the dysesthesia of these conditions in human subjects.

Abstract: Disclosed are bolus compositions for use in the treatment or prevention of hypocalcemia and choline deficiency in ruminants. The bolus compositions may comprise rumen-protected choline, one or more calcium salts, and water.

Abstract: The application relates to cationic lipids and to compositions comprising said cationic lipids useful for the delivery of nucleic acids into living cells.

Abstract: Compounds are provided having the following structure: (I) or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, wherein G1, R1, R2, L, and n are as defined herein. Use of the compounds as a component of lipid nanoparticle formulations for delivery of a therapeutic agent, compositions comprising the compounds and methods for their use and preparation are also provided.

Abstract: The embodiments of the present invention relate to a stable liquid vigabatrin pharmaceutical compositions in the liquid form of a solution. Particularly, the stable vigabatrin liquid pharmaceutical composition is manufactured as a ready-to-use industrialized premixture that does not require reconstitution or dilution prior to administration to a patient. The vigabatrin liquid pharmaceutical composition is stable six months or longer at room temperature and has levels of total impurities and Vigabatrin-related compound A that are both not more than 0.04% at, or prior to, six months. In some embodiments, the composition has improved stability and patient compliance. In some embodiments, the compositions may be advantageous for the patients having swallowing difficulties or when the patients are unable to take solid oral dosage forms. In some embodiments, the composition improves compliance with ketogenic diet.

Abstract: An antigen-loaded nanogel is formed by loading or encapsulating one or more long peptide antigens or one or more protein antigens in a hydrophobized polysaccharide. The long peptide antigen(s) or protein antigen(s) contains (or each contain) one or more CD8+ cytotoxic T cell recognition epitopes and/or one or more CD4+ helper T cell recognition epitopes, which is/are derived from the antigen. The antigen-loaded nanogel is administered at least one day prior to administration of antigen-specific T cells to improve the efficacy of a T cell infusion therapy against an immune checkpoint inhibitor-resistant tumor. The hydrophobized polysaccharide may be pullulan having cholesteryl groups bound thereto. An immune-enhancing agent also may be administered in or with the antigen-loaded nanogel.

Abstract: Phytosphingosine derivatives suitable as adjuvants in immune stimulation, pharmaceutical compositions comprising such compounds and the medical use of the compounds and/or compositions in therapeutic or prophylactic methods of immune stimulation in a subject, and for use in the treatment of a disease, for which stimulation of an immune response in a subject produces a therapeutic benefit. The phytosphingosine derivative may also be used as adjuvants in vaccinating a subject. The phytosphingosine derivative may also be used in stimulating antibody production, stimulating an immune response against infection, stimulating an immune response against a cancer, or preventing and/or treating septic shock. Methods for the manufacture of the derivatives comprising an Ugi-4-component reaction (Ugi-4CR) is also disclosed.

Abstract: As described below, the present invention features compositions and methods for treating brain and/or behavioral health disorders and their associated symptoms.

Abstract: The present invention provides an mRNA molecule encoding at least one KRAS variant peptide. Further, the invention provides a pharmaceutical composition and kit comprising the mRNA molecule. The mRNA molecule, pharmaceutical composition and kit are useful for treating cancer.

Abstract: The invention relates to a pharmaceutical formulation, e.g. a paediatric formulation, of odevixibat, which comprises a plurality of small particles. The formulation may be used in the treatment of liver diseases such as bile acid-dependent liver diseases, and particularly cholestatic liver diseases such as biliary atresia, progressive familial intrahepatic cholestasis (PFIC), Alagille syndrome (ALGS) and paediatric cholestatic pruritus. The invention also relates to a process for the preparation of the pharmaceutical formulation.

Abstract: Provided herein are compositions of trehalose phospholipids and uses thereof, e.g., compounds and compositions comprising 6,6?-diphosphatidyltrehalose (diPT) and analogs thereof with modifications of the diPT chemical scaffold, that bind and agonize Mincle, and the use thereof as adjuvants.